Educational programs building upon the most current research and professional practice recommendations in thoracic cancer, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
08-10-2018 | Lung cancer | Scientific summary | Collection
The symposium discussed the latest in non-driver mutation lung cancer, from histologic and molecular profiling, through to current and emerging treatment options, including those for patients with refractory and aggressive disease. The objective was to discuss the challenges that this patient group presents, and the progress being made to overcome them.
This program was made possible thanks to an independent educational grant from Eli Lilly and Company.
This symposium provides practical advice for clinicians treating NSCLC in an increasingly intricate therapeutic landscape. The expert Faculty guides the audience through case studies covering the harder-to-treat squamous NSCLC patient and the increasingly complex problem of what is the best approach for adenocarcinoma patients who rapidly progress. This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.
This symposium, held in Panama City, aimed to facilitate the management of squamous and non-squamous NSCLC. It addressed the challenges facing clinicians in the Latin-American region by placing the latest developments in advanced NSCLC into the context of treatment. The expert Faculty provided their insights into how biological knowledge can be used not only to improve treatment pathways, but to maximize outcomes by understanding different treatment approaches. This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.
The expert Faculty guided us through this complexity by placing the latest developments in advanced NSCLC into the context of treatment. They provided their insights into how we can use our biological knowledge not only to improve treatment pathways, but also to maximize treatment outcomes by understanding different approaches. The scientific summary includes questions that were put to the audience by the Chair, Professor Tony Mok. This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.
The faculty provided insight and guidance on the latest developments when treating NSCLC and how we can use our biological knowledge to improve both treatment pathways and outcomes in NSCLC. The scientific summary includes a presentation from Keith Kerr on trail markers in squamous NSCLC, a case study, presented by Johan Vansteenkiste and a panel discussion on patient management in the targeted age, Martin Reck. This program is made possible thanks to independent educational sponsorship from Eli Lilly and Company.
This is an interactive case study presented by Johan Vansteenkiste, based on a patient case discussed a Springer Healthcare independent symposium at the ELCC 2016.
The purpose of this interactive case study of is for participants to test their knowledge and clinical practices in the management of patients with NSCLC, and gain knowledge of emerging first-line and relapse treatment pathways.
An independent satellite symposium held in conjunction with the 17th European Congress: Perspectives in Lung Cancer. PILC provides a unique environment for a focused dialogue among experts in lung cancer. It is within this environment that we provided a highly interactive learning experience for international Health Care Professionals that care for patients with advanced NSCLC. The symposium adopted a case-focussed approach with the aim of aiding attendees in confirming their current practices and optimizing their patient care. This programme was made possible thanks to an educational grant received from Eli Lilly and Company.